OCS OCULIS HOLDING AG

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company.

Attachment



EN
09/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE

Oculis Upsized Loan Facility to Access up to CHF 100 million

Oculis Upsized Loan Facility to Access up to CHF 100 million ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”). The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, an...

 PRESS RELEASE

Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum ...

Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum CHF ZUG, Sviss, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknifyrirtæki með áherslu á nýsköpun við meðferð á augn- og augntaugasjúkdómum í því skyni að mæta verulegum óuppfylltum læknisfræðilegum þörfum, greinir frá því í dag að breytingar hafa verið gerðar á lánssamningi félagsins („breytti lánssamningurinn“) við sjóði í stýringu hjá BlackRock („lánveitandi“). Breytti lánasamningurinn kemur í stað fyrri lánssamnings, sem gerður var þann 29. m...

 PRESS RELEASE

Oculis Upsized Loan Facility to Access up to CHF 100 million

Oculis Upsized Loan Facility to Access up to CHF 100 million ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”). The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, an...

 PRESS RELEASE

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company. Attachment

 PRESS RELEASE

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, June 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the annual equity incentive awards granted to directors of the Company. Attachments

ResearchPool Subscriptions

Get the most out of your insights

Get in touch